Pharmaceutical product development involves transforming an active pharmaceutical ingredient (API) into a suitable dosage form that can be consistently manufactured, safely stored, effectively administered, and reliably deliver the intended therapeutic performance. Robust formulation development integrates API characteristics, excipient functionality, dosage-form design, manufacturing processes, analytical performance, packaging, and patient requirements through a systematic, science and risk-based development approach.
The most effective approach is to identify those risks early, use scientific evidence to guide decisions, and carry development knowledge into scale-up, validation, and commercial manufacturing. This is consistent with the principles behind ICH Q8, Q9 and Q10, which connect pharmaceutical development, quality risk management and the pharmaceutical quality system.
This article breaks down where that risk actually comes from, how an integrated approach addresses it at each stage, and what pharmaceutical manufacturers from early-stage startups to established B2B pharma companies should look for when evaluating a development partner in the UK, EU, or global market.
What Is Pharmaceutical Product Development?
Pharmaceutical formulation, or Product development, is the scientific process of combining an active pharmaceutical ingredient (API) with appropriate excipients while selecting a suitable dosage form and manufacturing process. The objective extends beyond simply combining the API with inactive ingredients; a well-designed formulation must consistently deliver the intended product quality and performance throughout manufacturing, storage, distribution, and patient use.
Drug formulation involves designing the composition and dosage form of a pharmaceutical product to ensure that the active pharmaceutical ingredient (API) achieves the desired quality, stability, manufacturability, and therapeutic performance. The development process typically encompasses pre-formulation studies, dosage-form selection, excipient screening and selection, API–excipient compatibility assessment, prototype formulation, dissolution or drug-release testing, stability evaluation, process development, scale-up, and establishment of an appropriate control strategy.
ICH Q8(R2) promotes a science and risk-based approach to pharmaceutical development and provides a framework for applying Quality by Design (QbD) principles. However, it does not require every product to follow an identical development model or mandate the establishment of a formal design space. Instead, the development strategy should be tailored to the specific product, dosage form, manufacturing process, associated risks, and level of available scientific knowledge.
The objective is not simply to produce a product that works once. The development process should build enough product and process understanding to support consistent quality throughout the product lifecycle.
Sciom's product development offering includes pre-formulation assessment and pharmaceutical formulation development, evaluating API and excipient physicochemical properties for tablets, injectables, solutions and suspensions.
Explore Sciom's pharmaceutical product development services
ICH Q8(R2), QbD and Pharmaceutical Development
ICH Q8(R2) Pharmaceutical Development is a key harmonised guideline for the development of pharmaceutical drug products. It emphasises the importance of establishing scientific knowledge and understanding of both the product and its manufacturing process. The knowledge generated throughout development can be used to support product specifications, manufacturing controls, risk management, and ongoing lifecycle management.
The guideline also outlines the principles of Quality by Design (QbD), in which quality is built into the product and manufacturing process through systematic scientific understanding rather than relying solely on end-product testing.
- Quality Target Product Profile (QTPP): A prospective summary of the desired characteristics of the finished pharmaceutical product, defined according to its intended use, safety, quality, and performance requirements.
- Critical Quality Attributes (CQAs): Physical, chemical, biological, or microbiological properties that should remain within appropriate limits to ensure the desired product quality and performance. Depending on the dosage form, CQAs may include assay, content uniformity, dissolution, degradation products, moisture, pH, viscosity, particle size, sterility, endotoxin levels, microbial quality, preservative efficacy, and other relevant attributes.
- Critical Material Attribute (CMA): A physical, chemical, or biological property of a raw material or component that can influence a CQA and, consequently, the quality or performance of the finished product.
- Critical Process Parameter (CPP): A process parameter whose variability can have a significant impact on one or more CQAs and therefore requires appropriate monitoring or control to ensure consistent product quality.
- Control Strategy: A planned and scientifically justified set of controls, developed from product and process understanding, that ensures the manufacturing process consistently produces a product meeting its predefined quality requirements.
Formulation Optimization and Design of Experiments (DoE)
Formulation optimization should be guided by clearly defined scientific objectives and an understanding of the factors that may influence product performance. While traditional one-factor-at-a-time (OFAT) studies can be appropriate for certain development activities, multivariable approaches such as Design of Experiments (DoE) provide a more systematic means of evaluating formulation and process variables, including potential interactions between them.
For example, during tablet development, a DoE study may investigate the effects and interactions of variables such as:
- Disintegrant concentration;
- Binder concentration;
- Lubricant concentration;
- Granulation liquid quantity
- Compression force.
The resulting product responses may include tablet hardness, friability, disintegration time, dissolution, and content uniformity. The primary value of DoE lies not in the software or statistical tool itself, but in generating structured scientific knowledge about how formulation and process variables influence product quality and performance.
Analytical Method Development
Analytical methods provide evidence needed to understand and control product quality, including identity, potency, purity, impurities and stability.
Poorly understood or unsuitable methods can create downstream problems, generate unreliable results or become difficult to transfer into routine quality control.
ICH Q2(R2) covers validation of analytical procedures, while Q14 addresses analytical procedure development.
Sciom supports analytical method development for pharmaceutical quality control, including potency, purity and stability assessment.
Analytical method development services
Microbial Quality and Preservative Strategy
pharmaceutical development, microbial quality should be considered as part of the overall formulation and manufacturing control strategy. For non-sterile products, control is achieved through appropriate raw-material quality, hygienic manufacturing, formulation design, microbiological controls, and suitable packaging.
For aqueous or multidose formulations, antimicrobial preservatives may be used where justified to limit microbial proliferation during storage and in-use conditions. Preservative selection should consider antimicrobial spectrum, concentration, formulation pH, API–excipient compatibility, chemical stability, patient safety, and container-closure interactions.
Scale-Up and Technology Transfer
Scale-up from laboratory to pilot and commercial manufacturing involves more than simply increasing the quantities of materials and proportionally adjusting process parameters. Changes in equipment geometry, mixing and shear energy, heat and mass transfer, drying kinetics, material flow, processing and hold times, and compression behaviour can significantly influence process performance and product quality at larger scales.
Technology transfer should therefore ensure that the product and process knowledge generated during development is effectively transferred to the manufacturing environment. A comprehensive technology-transfer package would typically include:
- Formulation composition and relevant material attributes;
- Manufacturing instructions, process parameters, and the scientific rationale for the process;
- Identified CQAs, CMAs, and CPPs;
- Established acceptable or justified operating ranges, where applicable;
- In-process controls and sampling strategies;
- Analytical methods and associated requirements;
- Known failure modes, risks, and relevant development history; and
- Packaging specifications and stability requirements.
Sciom's product development services include technology transfer and manufacturing scale-up, supporting movement from laboratory development toward pilot and commercial-scale manufacturing.
Process Validation and Manufacturing Control
Process validation provides documented evidence that a manufacturing process can consistently produce a product meeting predetermined quality requirement.
It should not be viewed as a single event at the end of development. FDA's process validation guidance describes a lifecycle approach involving process design, process qualification and continued process verification, supported by science and risk-based decision-making.
Sciom provides pharmaceutical process validation services as part of its product development capabilities.
Stability Testing and Shelf-Life Confidence
Stability assessment should not be treated as a final verification step after formulation development; rather, it should be integrated into the formulation design process from an early stage. Stability studies of prototype formulations can help identify potential issues such as chemical degradation, moisture sensitivity, physical instability, precipitation, changes in dissolution performance, preservative efficacy concerns, and interactions with packaging materials.
The container-closure system is also an integral component of the overall stability strategy. Its design and material properties can influence moisture protection, oxygen and light exposure, adsorption, the potential for extractables and leachables, product delivery, and in-use performance. Consequently, packaging selection should be considered alongside formulation and process development to ensure the product remains within its intended quality and performance requirements throughout its shelf life.
Sciom provides ICH-compliant stability testing programmes to support assessment of shelf-life, storage conditions and long-term product stability.
Sciom stability testing services
Regulatory Documentation and Data Integrity
Development decisions depend on supporting information being complete, traceable and properly controlled. Documentation is therefore part of pharmaceutical development risk management.
Important records can include development data, validation protocols, batch records and CTD documentation. Data integrity principles help ensure information remains attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring and available.
Sciom states that its regulatory and development documentation processes support CTD submissions, batch records and validation protocols, with data integrity practices aligned with ICH Q7, Q9 and Q10 and ALCOA+ principles.
How Quality Risk Management Supports Pharmaceutical Development
The relationship can be viewed simply:
ICH Q8 focuses on pharmaceutical development and building product and process understanding. ICH Q9 provides principles and tools for quality risk management. ICH Q10 establishes a pharmaceutical quality system designed to support control and continual improvement across the product lifecycle.
For development teams, this means risk assessment should influence decisions about experiments, controls, analytical strategies, process parameters and validation activities. Higher-risk areas generally warrant greater attention and stronger controls, while lower-risk areas may require less intensive investigation when scientifically justified.
Risk management does not eliminate uncertainty. It provides a structured way to understand uncertainty and make decisions using available evidence.
Why an Integrated Development Approach Can Reduce Risk
Pharmaceutical development activities are interconnected:
A formulation decision can affect analytical testing. Analytical knowledge can influence process understanding. Scale-up can reveal process variables that were less significant at laboratory scale. Stability results can prompt further formulation or packaging assessment. Validation depends on the knowledge generated during development.
Separating these activities too rigidly can create gaps between teams, duplicate work or make important information harder to carry forward.
An integrated pharmaceutical development partner can help connect these activities. Sciom's product development and CDMO offerings cover formulation support, analytical method development, technology transfer, scale-up, stability studies and quality-related activities across development and manufacturing.
How Sciom Supports Pharmaceutical Product Development
Sciom is a UK-based pharmaceutical service provider built specifically around this integrated model. Rather than offering isolated services, Sciom coordinates the full spectrum of CDMO services formulation development, analytical method validation, and stability studies alongside regulatory affairs (including global submissions and gap analysis), pharmacovigilance, GMP/GDP compliance and audit support, and validation and qualification (IQ/OQ/PQ).
What makes this relevant to risk management in drug development isn't the range of services on its own it's that they sit under one coordinated structure. A formulation change doesn't get lost before it reaches the regulatory team. A compliance gap identified during an internal audit doesn't sit unaddressed because "that's someone else's contract." For pharmaceutical manufacturers entering the UK or EU market, or for smaller companies without a large in-house regulatory function, that coordination is often the single biggest factor in whether a submission goes smoothly or gets delayed by preventable issues.
Conclusion
Pharmaceutical product development requires continuous product and process understanding, with risks identified and managed from pre-formulation through formulation, analytical testing, scale-up, validation, stability and regulatory documentation. A science and risk-based approach helps teams make informed decisions, strengthen controls and reduce avoidable problems later in development and manufacturing.
With capabilities across pre-formulation, formulation development, analytical method development, technology transfer, manufacturing scale-up, process validation, stability testing and regulatory documentation, Sciom supports key stages of the pharmaceutical development journey. This integrated approach helps connect scientific development with quality, compliance and manufacturing readiness.
Frequently Asked Questions
References
The following official resources provide additional information on AI, pharmacovigilance, and global regulatory expectations:
- Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products - Scientific guideline
- Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improved
- Mitigating the Risks of Generic Drug Product Development: An Application of Quality by Design (QbD) and Question-based Review (QbR) Approaches
- Early Drug Discovery and Development Guidelines
- Quality risk management in pharmaceutical development